If erythropoietin (EPO) level is elevated, what is the next step in evaluation?

Elevated EPO: Next Steps in Evaluation

When erythropoietin (EPO) levels are elevated, the next step is to systematically evaluate for secondary causes of polycythemia by measuring arterial oxygen saturation, obtaining imaging studies of the kidneys and other organs, and checking for EPO-producing tumors or hypoxic conditions. 1

Diagnostic Algorithm for High EPO

An elevated EPO level strongly suggests secondary polycythemia rather than polycythemia vera (PV), as PV typically presents with low or subnormal EPO levels 2. However, the evaluation must be thorough and systematic.

Initial Laboratory Assessment

When EPO is elevated in the context of erythrocytosis:

• Measure arterial oxygen saturation and carboxyhemoglobin levels - particularly important in smokers to identify hypoxic states 1
• Check P50 (oxygen pressure at 50% hemoglobin-oxygen saturation) - A low P50 indicates high oxygen-affinity hemoglobinopathy or 2,3-diphosphoglycerate mutase deficiency 1
• Verify iron status - Check serum ferritin and transferrin saturation, as iron deficiency can complicate the picture 1

Imaging Studies

Perform renal vascular studies and imaging to rule out:

• Renal artery stenosis
• Renal tumors or cysts (EPO-producing lesions)
• Hepatocellular carcinoma
• Central nervous system lesions 1

Important Clinical Caveat

Budd-Chiari syndrome represents a critical exception: Patients with hepatic vein thrombosis can have PV with paradoxically elevated EPO levels 3, 4. In these cases, JAK2 V617F mutation testing becomes essential to confirm PV despite the elevated EPO 3.

Specific Conditions to Evaluate

Based on the elevated EPO finding, investigate:

1. Hypoxic conditions:

   • Chronic obstructive pulmonary disease (COPD)
   • Cyanotic congenital heart disease
   • High altitude residence
   • Sleep apnea 1

2. Inappropriate EPO production:

   • Renal cell carcinoma
   • Hepatocellular carcinoma
   • Cerebellar hemangioblastoma
   • Uterine fibroids 1

3. Congenital causes (especially in young patients or those with family history):

   • High oxygen-affinity hemoglobinopathies
   • EPO receptor mutations
   • 2,3-DPG mutase deficiency 1, 5

4. Post-renal transplant erythrocytosis - Consider ACE inhibitors or angiotensin II receptor blockers as both diagnostic and therapeutic 1

When to Consider JAK2 Testing Despite High EPO

Order JAK2 V617F mutation testing if:

• Patient presents with Budd-Chiari syndrome or unusual thrombosis 3, 4
• Other PV-related features are present (splenomegaly, thrombocytosis, leukocytosis, aquagenic pruritus) 1
• No clear secondary cause is identified after initial workup 5

Management Based on Etiology

The treatment approach depends entirely on the underlying cause:

• COPD or hypoxic states: Judicious phlebotomy to hematocrit 55-60% may improve exercise tolerance; theophylline can lower hematocrit 1
• Post-renal transplant: ACE inhibitors are first-line therapy 1
• Tumor-related: Address the underlying malignancy
• High oxygen-affinity hemoglobinopathy: Avoid aggressive phlebotomy due to stroke risk; target hematocrit ~60% 1

Key Pitfall to Avoid

Do not automatically exclude PV based solely on elevated EPO - approximately 3-13% of PV patients may have normal or even elevated EPO levels, particularly in the setting of hepatic vein thrombosis 6, 3, 4. The combination of clinical features, bone marrow histology, and JAK2 mutation status provides the definitive diagnosis 2.